137 related articles for article (PubMed ID: 38804898)
1. Quantum Mechanical Assessment of Nitrosamine Potency.
De S; Thapa B; Sayyed FB; Frank SA; Cornwell PD; Jolly RA
Chem Res Toxicol; 2024 Jun; 37(6):1011-1022. PubMed ID: 38804898
[TBL] [Abstract][Full Text] [Related]
2. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
[TBL] [Abstract][Full Text] [Related]
3. Computational Prediction of Metabolic α-Carbon Hydroxylation Potential of
Chakravarti S
Chem Res Toxicol; 2023 Jun; 36(6):959-970. PubMed ID: 37267457
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency.
Snodin DJ; Trejo-Martin A; Ponting DJ; Smith GF; Czich A; Cross K; Custer L; Elloway J; Greene N; Kalgutkar AS; Stalford SA; Tennant RE; Vock E; Zalewski A; Ziegler V; Dobo KL
Chem Res Toxicol; 2024 Feb; 37(2):181-198. PubMed ID: 38316048
[TBL] [Abstract][Full Text] [Related]
5. Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines.
Snodin DJ
Regul Toxicol Pharmacol; 2023 Jun; 141():105403. PubMed ID: 37116739
[TBL] [Abstract][Full Text] [Related]
6. The carcinogenic significance of reactive intermediates derived from 3-acetoxy- and 5-acetoxy-2-hydroxy-N-nitrosomorpholine.
Loeppky RN; Sukhtankar S; Gu F; Park M
Chem Res Toxicol; 2005 Dec; 18(12):1955-66. PubMed ID: 16359186
[TBL] [Abstract][Full Text] [Related]
7. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
[TBL] [Abstract][Full Text] [Related]
8. NITROSOGENESIS, ANTIDEPRESSANTS AND THE SERTRALIN INDUCED NEVUS ASSOCIATED CUTANEOUS MELANOMA: THE NDMA/ NNK (NDSRIS) CONTAMINATION AS MOST POTENT MELANOMA INDUCTORS: ALEA IACTA EST.
Tchernev G
Georgian Med News; 2023 Sep; (342):47-53. PubMed ID: 37991956
[TBL] [Abstract][Full Text] [Related]
9. Nitrosamine acceptable intakes should consider variation in molecular weight: The implication of stoichiometric DNA damage.
Fine J; Allain L; Schlingemann J; Ponting DJ; Thomas R; Johnson GE
Regul Toxicol Pharmacol; 2023 Dec; 145():105505. PubMed ID: 37805106
[TBL] [Abstract][Full Text] [Related]
10. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
[TBL] [Abstract][Full Text] [Related]
11. METASTATIC NODULAR MELANOMA DEVELOPING ON NEVUS SPILUS DURING INTAKE OF BETA BLOCKERS (BISOPROLOL/NEBIVOLOL) AND ACE INHIBITORS (PERINDOPRIL). POTENTIAL LINKS TО THE DRUG RELATED NITROSOGENESIS/CARCINOGENESIS, DUNNING-KRUGER EFFECT AND GENETIC WEAPONS OF THE NEW GENERATION.
Tchernev G
Georgian Med News; 2023 Oct; (343):172-178. PubMed ID: 38096536
[TBL] [Abstract][Full Text] [Related]
12. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.
Burns MJ; Ponting DJ; Foster RS; Thornton BP; Romero NE; Smith GF; Ashworth IW; Teasdale A; Simon S; Schlingemann J
J Pharm Sci; 2023 Dec; 112(12):3005-3011. PubMed ID: 37805074
[TBL] [Abstract][Full Text] [Related]
14. MORPHEAFORM BCC OF ALA NASI: A SUCCESSFUL DERMATOSURGICAL APPROACH BY TRANSPOSITION FLAP FROM THE ADJACENT AREA. CONTAMINATION OF VENLAFAXINE, BISOPROLOL AND OLANZAPINE WITH NITROSAMINES/NDSRIS: THE MOST LIKELY CAUSE OF SKIN CANCER DEVELOPMENT AND PROGRESSION.
Tchernev G; Lozev I; Ivanov L
Georgian Med News; 2023 Sep; (342):26-29. PubMed ID: 37991952
[TBL] [Abstract][Full Text] [Related]
15. [N-nitroso compounds. Analysis and possible carcinogenicity in man].
Griciute L
IARC Sci Publ (1971); 1976; (13):375-85. PubMed ID: 1002182
[TBL] [Abstract][Full Text] [Related]
16. Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s.
Li X; He X; Le Y; Guo X; Bryant MS; Atrakchi AH; McGovern TJ; Davis-Bruno KL; Keire DA; Heflich RH; Mei N
Arch Toxicol; 2022 Nov; 96(11):3077-3089. PubMed ID: 35882637
[TBL] [Abstract][Full Text] [Related]
17. Predicting DNA-Reactivity of N-Nitrosamines: A Quantum Chemical Approach.
Wenzel J; Schmidt F; Blumrich M; Amberg A; Czich A
Chem Res Toxicol; 2022 Nov; 35(11):2068-2084. PubMed ID: 36302168
[No Abstract] [Full Text] [Related]
18. MELANOMA AND DYSPLASTIC NEVI DEVELOPMENT AFTER RANITIDINE/RILMENIDINE/МOXONIDINE, LERCANIDIPINE, ROSUVASTATIN AND VERAPAMIL/TRANDOLAPRIL - NEW DATA/CASE SERIES. THE POTENTIAL ROLE OF NITROSAMINE/NDSRIS CONTAMINATION IN POLYMEDICATION AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR.
Tchernev G; Naydekova N
Georgian Med News; 2023 Nov; (344):152-158. PubMed ID: 38236117
[TBL] [Abstract][Full Text] [Related]
19. The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.
Schlingemann J; Burns MJ; Ponting DJ; Martins Avila C; Romero NE; Jaywant MA; Smith GF; Ashworth IW; Simon S; Saal C; Wilk A
J Pharm Sci; 2023 May; 112(5):1287-1304. PubMed ID: 36402198
[TBL] [Abstract][Full Text] [Related]
20. Maximizing use of existing carcinogenicity data to support acceptable intake levels for mutagenic impurities in pharmaceuticals: Learnings from N-nitrosamine case studies.
Felter SP; Ponting DJ; Mudd AM; Thomas R; Oliveira AAF
Regul Toxicol Pharmacol; 2023 Sep; 143():105459. PubMed ID: 37474097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]